Patents by Inventor Scott Channing Sutton
Scott Channing Sutton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240140947Abstract: The invention relates to 4-((6-(2,2-Difluoroethyl)-8-(2-hydroxy-2-methylcyclopentyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)piperidine-1-sulfonamide or pharmaceutically acceptable salts thereof, to compositions containing them, to processes for their preparation, to intermediates used in such processes, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer. The disclosure also relates to its crystalline form 1, to pharmaceutical compositions comprising form 1, and to the use of form 1 for the treatment of cancers.Type: ApplicationFiled: October 17, 2023Publication date: May 2, 2024Applicant: Pfizer Inc.Inventors: Fengjuan Cao, Kevin Daniel Freeman-Cook, Rhys Marsden Jones, Scott Channing Sutton
-
Patent number: 11773082Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.Type: GrantFiled: April 20, 2021Date of Patent: October 3, 2023Assignee: PFIZER INC.Inventors: Douglas Carl Behenna, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Asako Nagata, Sacha Ninkovic, Scott Channing Sutton
-
Patent number: 11718603Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.Type: GrantFiled: April 20, 2021Date of Patent: August 8, 2023Assignee: PFIZER INC.Inventors: Douglas Carl Behenna, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Asako Nagata, Sacha Ninkovic, Scott Channing Sutton
-
Publication number: 20230174522Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Ring A, R1-R8, and n are defined herein. The novel benzisoxazole sulfonamide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in patients.Type: ApplicationFiled: September 16, 2022Publication date: June 8, 2023Inventors: Ylva Elisabet Bergman Bozikis, Oleg Brodsky, Michelle Ang Camerino, Samantha Elizabeth Greasley, Robert Louis Hoffman, Robert Arnold Kumpf, Pei-Pei Kung, Paul Francis Richardson, Paul Anthony Stupple, Scott Channing Sutton
-
Patent number: 11492346Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Ring A, R1-R8, and n are defined herein. The novel benzisoxazole sulfonamide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in patients.Type: GrantFiled: June 16, 2020Date of Patent: November 8, 2022Assignees: Pfizer Inc., CTXT PTY LTDInventors: Ylva Elisabet Bergman Bozikis, Michelle Ang Camerino, Pei-Pei Kung, Paul Anthony Stupple, Scott Channing Sutton
-
Publication number: 20210269425Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.Type: ApplicationFiled: April 20, 2021Publication date: September 2, 2021Applicant: Pfizer Inc.Inventors: Douglas Carl Behenna, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Asako Nagata, Sacha Ninkovic, Scott Channing Sutton
-
Publication number: 20210261530Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.Type: ApplicationFiled: April 20, 2021Publication date: August 26, 2021Applicant: Pfizer Inc.Inventors: Douglas Carl Behenna, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Asako Nagata, Sacha Ninkovic, Scott Channing Sutton
-
Patent number: 11014911Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.Type: GrantFiled: January 28, 2020Date of Patent: May 25, 2021Assignee: Pfizer Inc.Inventors: Douglas Carl Behenna, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Asako Nagata, Sacha Ninkovic, Scott Channing Sutton
-
Publication number: 20200399258Abstract: The present invention relates to compounds of formula (1) or pharmaceutically acceptable salts thereof, wherein Ring A, R1-R8, and n are defined herein. The novel benzisoxazole sulfonamide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in patients.Type: ApplicationFiled: June 16, 2020Publication date: December 24, 2020Inventors: Ylva Elisabet Bergman Bozikis, Oleg Brodsky, Michelle Ang Camerino, Samantha Elizabeth Greasley, Robert Louis Hoffman, Robert Arnold Kumpf, Pei-Pei Kung, Paul Francis Richardson, Paul Anthony Stupple, Scott Channing Sutton
-
Publication number: 20200247784Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.Type: ApplicationFiled: January 28, 2020Publication date: August 6, 2020Applicant: Pfizer Inc.Inventors: Douglas Carl Behenna, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Asako Nagata, Sacha Ninkovic, Scott Channing Sutton
-
Patent number: 10570121Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.Type: GrantFiled: October 10, 2018Date of Patent: February 25, 2020Assignee: Pfizer Inc.Inventors: Michael Raymond Collins, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
-
Patent number: 10246433Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.Type: GrantFiled: May 3, 2017Date of Patent: April 2, 2019Assignee: Pfizer Inc.Inventors: Martin Paul Edwards, Robert Arnold Kumpf, Pei-Pei Kung, Indrawan James McAlpine, Sacha Ninkovic, Eugene Yuanjin Rui, Scott Channing Sutton, John Howard Tatlock, Martin James Wythes, Luke Raymond Zehnder
-
Publication number: 20190040047Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.Type: ApplicationFiled: October 10, 2018Publication date: February 7, 2019Applicant: Pfizer Inc.Inventors: Michael Raymond Collins, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
-
Publication number: 20170298048Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.Type: ApplicationFiled: June 28, 2017Publication date: October 19, 2017Applicant: Pfizer Inc.Inventors: Michael Raymond Collins, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
-
Publication number: 20170233368Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.Type: ApplicationFiled: May 3, 2017Publication date: August 17, 2017Applicant: Pfizer Inc.Inventors: Martin Paul EDWARDS, Robert Arnold KUMPF, Pei-Pei KUNG, lndrawan James MCALPINE, Sacha NINKOVIC, Eugene Yuanjin RUI, Scott Channing SUTTON, John Howard TATLOCK, Martin James WYTHES, Luke Raymond ZEHNDER
-
Publication number: 20170152239Abstract: This invention relates to compounds of general formula in which R1, R2, R6, U, V, W, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, pharmaceutical compositions containing such compounds and salts, and to methods of using such compounds, salts and compositions.Type: ApplicationFiled: February 6, 2017Publication date: June 1, 2017Applicant: Pfizer Inc.Inventors: Martin Paul EDWARDS, Robert Arnold KUMPF, Pei-Pei KUNG, Indrawan James MCALPINE, Eugene Yuanjin RUI, Scott Channing SUTTON, John Howard TATLOCK, Martin James WYTHES
-
Publication number: 20160376254Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.Type: ApplicationFiled: September 12, 2016Publication date: December 29, 2016Applicant: Pfizer Inc.Inventors: Michael Raymond COLLINS, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
-
Patent number: 9481666Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.Type: GrantFiled: June 16, 2015Date of Patent: November 1, 2016Assignee: PFIZER INC.Inventors: Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Scott Channing Sutton, Martin James Wythes
-
Publication number: 20150361067Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.Type: ApplicationFiled: June 16, 2015Publication date: December 17, 2015Applicant: PFIZER INC.Inventors: Michael Raymond Collins, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
-
Publication number: 20150239842Abstract: This invention relates to compounds of general formula (I), in which R1, R2, R6, U, V, W, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, pharmaceutical compositions containing such compounds and salts, and to methods of using such compounds, salts and compositions.Type: ApplicationFiled: September 16, 2013Publication date: August 27, 2015Applicant: PFIZER INC.Inventors: Martin Paul Edwards, Robert Arnold Kumpf, Pei-Pei Kung, Indrawan James Mcalpine, Eugene Yuanjin Rui, Scott Channing Sutton, John Howard Tatlock, Martin James Wythes